Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access Protocol Thymus Transplantation for Immunodeficiency, Hematologic Malignancies, and Autoimmune Disease Related to Poor Thymic Function

NCT02274662 is registered in ClinicalTrials.gov with Sumitomo Pharma Switzerland GmbH as lead sponsor.

NCT NCT02274662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02274662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access Protocol Thymus Transplantation for Immunodeficiency, Hematologic Malignancies, and Autoimmune Disease Related to Poor Thymic Function
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2014
Completion date
August 31, 2023
Enrollment
11 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

athymia, immunodeficiency, immunoreconstitution, low t cell numbers, poor thymic function, thymus transplantation